New hope for COPD sufferers: drug targets high eosinophils to cut Flare-Ups

NCT ID NCT06897748

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This study tests a drug called tozorakimab in people with chronic obstructive pulmonary disease (COPD) who have a history of flare-ups and high levels of eosinophils (a type of white blood cell). The trial involves 98 participants who receive either tozorakimab or a placebo every two weeks for 12 weeks. The goal is to see if the drug improves lung function and reduces the number of COPD exacerbations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tozorakimab
What this could lead to: If successful, tozorakimab could become a new treatment option to reduce COPD flare-ups and improve breathing in patients with high eosinophils.
What could go wrong: This is an early Phase 2 trial with only 98 participants, so results may not apply to all COPD patients. The drug may not improve lung function or reduce exacerbations significantly, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

Research Site

Aramil, 624002, Russia
Research Site

Izhevsk, 426061, Russia
Research Site

Moscow, 105554, Russia
Research Site

Moscow, 117546, Russia
Research Site

Moscow, 119048, Russia
Research Site

Moscow, 125284, Russia
Research Site

Omsk, 644099, Russia
Research Site

Penza, 440067, Russia
Research Site

Perm, 614000, Russia
Research Site

Saint Petersburg, 193231, Russia
Research Site

Saratov, 410054, Russia
Research Site

Ulyanovsk, 432009, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.